[Clinical significance of serum levels of osteoproteherin and sclerostin in assessment of vascular calcification in chronic kidney disease stage 3-5].
| Autor: | Dzgoeva FU; North Ossetian State Medical Academy., Remizov OV; North Ossetian State Medical Academy., Botcieva VK; North Ossetian State Medical Academy., Goloeva VG; North Ossetian State Medical Academy., Malakhova NG; North Ossetian State Medical Academy., Ikoeva ZR; North Ossetian State Medical Academy. |
|---|---|
| Jazyk: | ruština |
| Zdroj: | Terapevticheskii arkhiv [Ter Arkh] 2022 Aug 04; Vol. 94 (6), pp. 731-737. Date of Electronic Publication: 2022 Aug 04. |
| DOI: | 10.26442/00403660.2022.06.201562 |
| Abstrakt: | Aim: To clarify the mechanisms of the effect of osteoprotegerin (OPG) and sclerostin on vascular calcification and the state of the cardiovascular system in chronic kidney disease (CKD). Materials and Methods: A total of 110 patients aged 18 to 65 years with CKD stages 35D were examined. OPG, sclerostin, intact parathyroid hormone, and serum troponin I were determined using the commercial "Enzyme-linked Immunosorbent Assay Kit for Sclerostin" from Cloude-Clone Corp. (USA) by enzyme-linked immunosorbent assay. Results: An increase in sclerostin and OPG levels was revealed, which significantly correlated with a decrease in glomerular filtration rate, as well as an increase in left ventricle myocardial mass index and peak systolic blood flow in the aortic arch. Conclusion: Changes in the regulation of bone-mineral metabolism, in which the proteins inhibitors of bone metabolism, OPG and sclerostin, as well as the interactive interaction between the vascular and skeletal systems, play a decisive role in the development of lesions of the cardiovascular system caused by vascular calcification in CKD. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|